[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiangya Hospital of Central South University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":640},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,55,0,25,[9,39,67,90,115,145,164,184,212,238,263,284,304,325,350,378,408,433,459,491,518,541,567,588,606],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100645157","the-impact-of-anxietydepression-on-the-efficacy-of-asthma-control-drugs-and-the-construction-of-a-predictive-model-for-the-risk-of-acute-asthma-attacks-100645157",false,"NCT07679321","The Impact of Anxiety\u002FDepression on the Efficacy of Asthma Control Drugs and the Construction of a Predictive Model for the Risk of Acute Asthma Attacks","Inclusion Criteria:\n\n* Diagnosis of asthma according to the Global Initiative for Asthma (GINA) 2024 criteria.\n* Male or female patients aged 14 years or older.\n* Complete clinical data available.\n* Newly diagnosed asthma or stable asthma.\n* Receiving asthma controller medication.\n\nExclusion Criteria:\n\n* History of major lung diseases other than asthma, congestive heart failure, cor pulmonale, or recent cardiac or thoracic surgery.\n* Incomplete medical records.\n* Cognitive impairment or inability to complete psychological scale assessments.\n* Clinically diagnosed acute or chronic mental disorders, such as bipolar disorder or schizophrenia.\n* Current use of antidepressant or anti-anxiety medications.\n* Pregnancy or lactation.","ALL","14 Years",{"count":19,"type":20},256,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this clinical trial is to explore the impact of anxiety\u002Fdepression on the efficacy of asthma controller medications and to develop a risk prediction model for asthma acute exacerbations in patients with asthma. It will also analyze the association between anxiety\u002Fdepression severity and asthma severity. The main questions it aims to answer are:\n\nDoes anxiety\u002Fdepression affect the therapeutic effect of asthma controller medications (e.g., asthma control level)? Can a reliable risk prediction model for asthma acute exacerbations be established based on anxiety\u002Fdepression and other relevant factors? Researchers will conduct a prospective observational study to collect and analyze data from participants, without additional interventions beyond standard clinical care, to explore the above research questions.\n\nParticipants will:\n\nComplete baseline assessments, including demographic information collection, medical history review, lung function tests, anxiety\u002Fdepression evaluations (via GAD-7 and PHQ-9 scales), and provide biological samples (induced sputum, feces, blood) Undergo follow-up visits at 3, 6, 12, 18, and 24 months after baseline Report asthma symptoms, acute exacerbation events, and cooperate with required clinical checkups during follow-up",[25],"Anxiety\u002FDepression and Asthma","RECRUITING","2026-06-28",{"date":29,"type":30},"2026-07-01","ACTUAL",{"date":32,"type":30},"2024-12-01",{"date":34,"type":20},"2027-12-30",{"name":36,"class":37},"Xiangya Hospital of Central South University","OTHER",1,{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":38},"100642490","effect-of-biologic-vs-synthetic-mesh-on-chronic-pain-after-laparoscopic-repair-of-contralateral-asymptomatic-hernia-in-patients-with-unilateral-symptomatic-inguinal-hernia-100642490","NCT07649434","Effect of Biologic vs Synthetic Mesh on Chronic Pain After Laparoscopic Repair of Contralateral Asymptomatic Hernia in Patients With Unilateral Symptomatic Inguinal Hernia","Effect of Biologic vs Synthetic Mesh on Chronic Pain After Laparoscopic Repair of Contralateral Asymptomatic Hernia in Patients With Unilateral Symptomatic Inguinal Hernia: a Multicenter, Single-blinded, Randomized Controlled Trial","BiSAH","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Unilateral symptomatic inguinal hernia with contralateral asymptomatic hernia (diagnosed either preoperatively as a clinically asymptomatic hernia or intraoperatively as an occult hernia)\n* Planned for laparoscopic transabdominal preperitoneal (TAPP) repair and consent to simultaneous repair of the contralateral asymptomatic hernia\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Incarcerated or strangulated hernia requiring emergency surgery\n* Inability to receive porcine-derived devices (religious or ethnic reasons)\n* Participation in other interventional trials within the last 6 months\n* Acute systemic infection or skin disease near the surgical site\n* Chronic pain syndrome or long-term use of analgesic medications\n* Pregnancy, planned pregnancy, or breastfeeding\n* Any condition judged by the investigator as unsuitable for trial participation","18 Years","80 Years",{"count":50,"type":20},90,"INTERVENTIONAL",[53],"NA","Inguinal hernia is one of the most common conditions in general surgery. In clinical practice, surgeons frequently face a dilemma: during the evaluation of a patient with unilateral symptomatic inguinal hernia, a contralateral asymptomatic defect is discovered-either preoperatively on physical examination or intraoperatively during laparoscopy. The question then becomes: how should this incidental finding be managed? Epidemiological data show that the incidence of such contralateral asymptomatic hernias can be as high as 20%. The management strategy for these hernias has changed considerably over time. Although traditional \"watchful waiting\" was once widely adopted, long-term follow-up studies have demonstrated that approximately 70% of asymptomatic patients eventually require surgery due to symptom progression, and increasing age is associated with higher surgical risks. Consequently, with the widespread adoption of laparoscopic techniques, simultaneous repair of asymptomatic hernias during the initial surgery has become a common clinical choice.\n\nHowever, this decision raises a critical question: how can the surgeon balance the need to repair the existing anatomical defect against the risk of introducing new long-term complications from the intervention? This makes the choice of repair material particularly important. Currently, synthetic polypropylene meshes, with their proven effectiveness in reducing recurrence rates, are considered the gold standard for inguinal hernia repair. However, as permanent implants, they may be associated with long-term complications-chronic postoperative pain and foreign body sensation, which affect patients' long-term quality of life.\n\nBiologic meshes offer a different option. Derived from decellularized extracellular matrix, they are designed as temporary scaffolds that guide autologous tissue regeneration and ultimately degrade. Theoretically, this avoids a permanent foreign body reaction and may reduce long-term discomfort. Nevertheless, the clinical value of biologic meshes in inguinal hernia repair remains controversial. Some studies suggest that biologic meshes reduce chronic pain and improve quality of life; others show no difference in pain or recurrence rates compared with synthetic meshes. Meta-analyses have not demonstrated clear superiority of biologic over synthetic meshes in overall complications, recurrence, or chronic pain, and the heterogeneity among existing studies is high.\n\nThe BIOLAP randomized clinical trial, published in JAMA Surgery in 2025, provided high-level evidence for symptomatic bilateral hernias. It showed that in laparoscopic inguinal hernia repair, biologic mesh did not significantly reduce postoperative pain. Moreover, it was associated with a significantly higher 2-year recurrence rate (11.2% vs. 2.5%) and a higher seroma rate (33.4% vs. 21.6%). However, a key question remains: can these conclusions be directly extrapolated to the setting of contralateral asymptomatic hernia repair, where the therapeutic goal is to maximize long term comfort rather than to relieve existing symptoms? The investigators previously conducted an exploratory single-center randomized controlled study (n=52, BiSOH) that addressed this question preliminarily. In that trial, the biologic mesh group had significantly lower inguinal pain scores at both 1 month and 6 months, with pain decreasing over time in both groups. Quality of life measured by SF-36 was significantly better in the biologic mesh group at both follow-up time points, and the EQ-5D score was higher at 6 months. These findings suggest that biologic mesh may offer advantages in chronic pain control and quality of life for occult hernia repair, contrasting with the BIOLAP conclusions. However, the single center design and methodological limitations prevented confirmation of the primary endpoint difference, highlighting the need for a multicenter, high-quality clinical trial.\n\nCurrently, international guidelines lack high level evidence on the optimal mesh type for simultaneous repair of contralateral asymptomatic hernias. Therefore, this multicenter, randomized, single-blinded, parallel-controlled trial was designed to compare biologic versus synthetic meshes in this specific scenario. The hypothesis is that the use of a biologic mesh (porcine UBM\u002FSIS composite) reduces chronic pain on the asymptomatic side at 6 months without increasing recurrence, compared with a synthetic mesh (self-gripping polyester).\n\nThe biologic mesh is a porcine urinary bladder matrix and small intestinal submucosa composite (UBM\u002FSIS) manufactured by ZR Medtech (Suzhou, China). It is a non-cross-linked, acellular, collagenous matrix produced through patented decellularization and antigen removal processes. It has been used for various soft tissue defect repairs.",[56,57],"Hernia Inguinal","Biologic Mesh","NOT_YET_RECRUITING","2026-06-14",{"date":61,"type":30},"2026-06-16",{"date":63,"type":20},"2026-06",{"date":65,"type":20},"2028-01",{"name":36,"class":37},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":38},"100643485","impact-of-radiotherapy-immunotherapy-timing-in-nsclc-brain-metastases-100643485","NCT07638709","Impact of Radiotherapy-Immunotherapy Timing in NSCLC Brain Metastases","Immune Microenvironment-driven Radiotherapy-immunotherapy Combined With Time-series Strategy for NSCLC Brain Metastases: an Exploratory Study Based on a Clinical Cohort.","(RT-ICI)","Inclusion Criteria:\n\n* Age ≥ 18 years; no gender restriction;\n* Histologically or cytologically confirmed NSCLC, with brain metastases confirmed by contrast-enhanced cranial MRI;\n* Scheduled to receive radiotherapy combined with a PD-1\u002FPD-L1 inhibitor, in accordance with real-world clinical treatment plans;\n* Negative for driver gene mutations, or positive for mutations but with documented failure of prior targeted therapy;\n* ECOG Performance Status score of 0-2, with an estimated life expectancy of ≥ 3 months;\n* Voluntarily signs the informed consent form and agrees to cooperate with blood\u002Fimaging data collection and follow-up procedures.\n\nExclusion Criteria:\n\n* History of whole-brain radiotherapy, stereotactic radiotherapy for brain metastases, or brain surgery;\n* Presence of contraindications to MRI or inability to tolerate gadolinium-based contrast agents (e.g., severe hepatic or renal insufficiency);\n* Presence of active autoimmune disease requiring systemic treatment, or requirement for long-term use of high-dose immunosuppressive agents;\n* Pregnant or lactating women;\n* Other circumstances deemed by the investigator to involve severe complications or render the patient unsuitable for enrollment.",{"count":76,"type":20},150,"2 Years","The goal of this observational study is to learn about the effects of the timing of radiation therapy and immunotherapy in adults with non-small cell lung cancer (NSCLC) that has spread to the brain. The main questions it aims to answer are:\n\n1. Does the timing of the two treatments change how long the brain tumor stays stable and how long participants live?\n2. What medical problems do participants have when receiving these treatments at different times?\n3. How does the timing of treatments affect the body's immune system?\n\nResearchers will compare participants who receive radiation and immunotherapy 30 days or less apart to those who receive them more than 30 days apart to see if the timing affects the treatment's success and safety.\n\nParticipants already receiving radiation and immunotherapy as part of their regular medical care will:\n\n1. Allow researchers to collect information about their treatment, health, and medical imaging during regular checkups.\n2. Give a small blood sample during their routine blood draws.\n3. Have standard magnetic resonance imaging (MRI) scans of their brain.",[80,81],"Non Small Cell Lung","Brain Metastasases","2026-06-09",{"date":84,"type":30},"2026-06-10",{"date":86,"type":20},"2026-06-05",{"date":88,"type":20},"2030-06-01",{"name":36,"class":37},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":16,"minAge":77,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":51,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":38},"100621387","repetitive-transcranial-magnetic-stimulation-combined-with-language-training-for-language-disorders-in-children-with-global-developmental-delay-100621387","NCT07369960","Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Global Developmental Delay","Randomized Controlled Study for Repetitive Transcranial Magnetic Stimulation Combined With Language Training in Children With Language Disorders in Children With Global Developmental Delay","Inclusion criteria\n\n1. Children aged 2-5 years old, regardless of gender.\n2. Meet the diagnostic definition of GDD in China's Diagnostic Guidelines for Global Developmental Delay (2024), confirmed by Gesell Developmental Schedules (GDS). Language domain Developmental Quotient (DQ) ≤ 75. A DQ ≤ 75 is found in at least one of the four developmental domains: gross motor, fine motor, adaptive behavior, and personal-social conduct. Mild-moderate GDD is selected for the study.\n3. The presence of significant language developmental delay, the language ability is significantly lower than children of the same age and the same intellectual level, confirmed by the standardized scale of Sign-Significate Relations (S-S) assessment.\n4. The child is able to cooperate with the completion of rTMS treatment and language assessment and has no serious behavioral problems.\n5. Written informed consent obtained from the child's legal guardian. Exclusion Criteria\n\n1\\. History of epilepsy or convulsive seizures. 2. Having metal implants in the skull (e.g. aneurysm clips, metal stents, etc.) and electronic devices such as pacemakers and cochlear implants in the body.\n\n3\\. Other serious neurological conditions that may affect language function (e.g., cerebral palsy, progressive neurological disorders, etc.).\n\n4\\. Have a diagnosis of ASD. 5. Have a severe hearing or visual impairment. 6. Participation in other clinical trials that may affect speech function. 7. Skin lesions or infection at the scalp treatment site. 8. The fontanelle has not yet closed. 9. Previous rTMS treatment in the last 3 months. 10. Developmental quotient \\\u003C 40 in any developmental domains; other circumstances that prevented cooperation with the study.","5 Years",{"count":99,"type":20},50,[53],"This study explores a safe and effective new approach to improve language function in children with Global Developmental Delay (GDD). Conducted at Xiangxi Autonomous Prefecture People's Hospital, the study will recruit approximately 50 children aged 2 to 5 years. Participants will be randomly assigned to one of two groups: one receiving personalized language training combined with non-invasive, painless repetitive Transcranial Magnetic Stimulation (rTMS) to activate language regions of the brain, and a control group receiving personalized training for comparative analysis. The study spans one month, including a two-week intervention period followed by a two-week follow-up to evaluate the efficacy and sustainability of the combined therapy. This study has been rigorously reviewed and approved by the hospital's Ethics Committee.",[103,104,105,106],"Developmental Delay Disorder","Repetitive Transcranial Magnetic Stimulation (rTMS)","Global Developmental Delay","Language Disorders in Children","2026-05-28",{"date":109,"type":30},"2026-06-02",{"date":111,"type":20},"2026-05-27",{"date":113,"type":20},"2026-12-31",{"name":36,"class":37},{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":122,"targetDuration":124,"studyType":22,"phases":4,"briefSummary":125,"conditions":126,"keywords":133,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":38},"100637209","multicenter-prospective-study-on-mri-ai-model-for-midline-glioma-subtyping-and-prognosis-100637209","NCT07608003","Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:","Application of MRI-Based Artificial Intelligence Models for Preoperative Molecular Subtyping and Prognostic Assessment of Midline Gliomas: A Multicenter Prospective Clinical Study","Inclusion Criteria:\n\n* Patients with diffuse gliomas were pathologically and molecularly diagnosed.\n* The clinical case data of all patients were complete.\n* Patients underwent preoperative MRI examination.\n\nExclusion Criteria:\n\n* The tumor is not located in the intracranial midline.\n* Cases in which MRI were incomplete or with significant noise and artifacts.",{"count":123,"type":20},500,"3 Years","A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p\u002F19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.",[127,128,129,130,131,132],"Gliomas Harboring IDH1 and\u002For IDH2 Mutations","Glioma Glioblastoma Multiforme","Glioma of Brainstem","Glioma, Diffuse Midline, H3K27M-mutant","Glioma : Oligodendroglioma or Astrocytoma","Gliomas",[134,135,136,137],"Midline gliomas","Molecular diagnosis","Foundation model","Prognosis prediction","2026-05-25",{"date":111,"type":30},{"date":141,"type":20},"2026-05-10",{"date":143,"type":20},"2030-12-31",{"name":36,"class":37},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":51,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":4},"100639114","effect-of-different-bed-head-angles-on-intraoperative-hypoxemia-in-patients-undergoing-painless-gastroenteroscopy-a-prospective-randomized-controlled-study-100639114","NCT07594951","Effect of Different Bed Head Angles on Intraoperative Hypoxemia in Patients Undergoing Painless Gastroenteroscopy: A Prospective Randomized Controlled Study","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Planned to undergo painless (sedated) gastrointestinal endoscopy\n3. Signed informed consent form\n4. American Society of Anesthesiologists (ASA) Physical Status classification I to III\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Emergency examination or inadequate bowel preparation\n3. Baseline peripheral oxygen saturation (SpO₂) \\\u003C 95%\n4. Patient or family members refuse to participate in the study",{"count":152,"type":20},400,[53],"Abstract:\n\nObjective: This study aimed to investigate the effect of different bed angles (0° vs. 15°) on the incidence of intraoperative hypoxemia in patients undergoing gastroscopy and colonoscopy. A prospective randomized controlled trial was conducted to evaluate the impact of patient positioning on respiratory safety, providing evidence for individualized anesthesia management.\n\nBackground:\n\nWith the increasing popularity of painless gastrointestinal endoscopy, hypoxemia has become a major safety concern in anesthesia management, particularly in elderly and obese patients. Studies have shown that the incidence of hypoxemia can exceed 26%, highlighting the importance of optimizing respiratory safety during anesthesia.\n\nMethods:\n\nA total of 400 patients scheduled for painless gastrointestinal endoscopy were recruited and randomly assigned to a control group (0° left lateral position) or an experimental group (15° left lateral position). Baseline data were recorded preoperatively. Intraoperative vital signs were monitored, and the occurrence of hypoxemia and other complications was documented. Data were collected and processed in a blinded manner, followed by statistical analysis using SPSS 26.0.",[156],"Hypoxemia","2026-05-18",{"date":159,"type":30},"2026-05-19",{"date":161,"type":20},"2026-05-01",{"date":29,"type":20},{"name":36,"class":37},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":170,"enrollmentInfo":171,"targetDuration":124,"studyType":22,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100630053","efficacy-and-safety-of-camrelizumab-plus-rivoceranib-and-local-therapy-for-hepatocellular-carcinoma-with-lung-metastases-caplocal--a-multicentre-single-armprospective-cohort-study-100630053","NCT07482670","Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria in order to be eligible for participation in this study:\n\n1. The patient voluntarily participates in this study and signs an informed consent form.\n2. Age: 18 to 85 years old, both male and female are eligible.\n3. Patients with hepatocellular carcinoma (HCC) confirmed through histopathological examination of tumor tissue or imaging assessments \\[refer to the Guidelines for the Diagnosis and Treatment of Primary Hepatocellular Carcinoma (2024 Edition)\\].\n4. There are extrahepatic pulmonary metastases that have not been treated locally, and the number of these metastases is ≤5.\n5. Has not received any form of systematic treatment for HCC.\n6. There must be at least one measurable lesion (according to the RECIST v1.1 criteria, this measurable lesion must have a longitudinal diameter ≥ 10 mm on spiral CT scans or a short diameter ≥ 15 mm for enlarged lymph nodes; lesions that have previously received local treatment and have clearly progressed according to the RECIST v1.1 standards can be considered target lesions).\n7. Neutrophil-to-lymphocyte ratio (NLR) of less than or equal to 3.\n8. The Child Pugh liver function classification is Grade A or B (≤7).\n9. The Eastern Cooperative Oncology Group (ECOG) behavioral status is 0 or 1 for patients in the eastern United States.\n10. Good lung function, expected to be able to tolerate surgery or localized treatment.\n11. Other major organ functions are generally normal (the blood system, kidneys, etc., function well).\n\n    Muscular marrow function is adequate: white blood cell count ≥ 4.0 × 10\\^9\u002FL, absolute neutrophil count (ANC) ≥ 2.0 × 10\\^9 \u002F L, platelet count ≥ 100 × 10 \\^ 9 \u002F L, hemoglobin concentration ≥ 90 g\u002FL (no blood transfusions, no use of hematopoietic factors, and no medication correction within 2 weeks prior to the first administration).\n\n    For patients not receiving anticoagulant therapy, the INR (International Normalized Ratio) and APTI (Activated Partial Thromboplastin Time) values are ≤ 1.5 times the upper limit of normal.\n\n    Sufficient renal function: creatinine clearance ≥ 60 mL\u002Fmin.\n12. Patients with active hepatitis B virus (HBV) infection must receive anti-HBV treatment prior to the initiation of the study treatment and must be willing to undergo antiviral therapy throughout the study period. Patients with hepatitis C virus (HCV) RNA-positive status must receive antiviral treatment according to local standard treatment guidelines and have liver function levels within the range of CTCAE Grade 1 elevation.\n13. Women of childbearing age should have a negative serum or urine pregnancy test within 7 days prior to enrollment in the study, and must be non-lactating patients who have given their consent to use contraceptive measures during the study period and for 6 months after its completion. Men must agree to use contraceptive measures both during the study period and within 6 months after its conclusion.\n14. The participant voluntarily consents to receive treatment related to this clinical study and agrees to participate in follow-up assessments.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will not be eligible to participate in this study:\n\n1. Known cases of cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma, and fibrolamellar cell carcinoma; having had an active malignant tumor other than HCC within 5 years or concurrently. Limited-stage tumors that have been cured, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial carcinoma, cervical intraepithelial carcinoma, and breast intraepithelial carcinoma, can be included.\n2. Has previously received anti-cancer treatments targeting metastatic lesions.\n3. The site of extrahepatic metastasis is not the lungs, or there are more than 2 distant metastasized organs (including 2).\n4. Suffering from any severe infection, serious mental or physical illness, or laboratory test abnormalities that are uncontrollable, which may pose an unacceptable risk, negatively impact trial compliance, or affect the administration, distribution, metabolism, and excretion of the investigational drug. Examples include unstable heart disease, chronic kidney disease, poorly controlled diabetes, mood disorders, mental disorders, central nervous system abnormalities, chronic diarrhea, ascites, and pleural effusions requiring treatment.\n5. Suffers from hypertension and cannot achieve adequate control with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg). It is permissible to use antihypertensive treatment to achieve these parameters. Has previously experienced a hypertensive crisis or hypertensive encephalopathy.\n6. Infection with human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) (or active viral hepatitis).\n7. Received experimental treatments from other clinical studies concurrently during the course of this trial.\n8. Long-term use of immunosuppressive agents following organ transplantation.\n9. According to the researchers' assessment, the subject may have other factors that could lead to the forced discontinuation of this study. These include non-compliance with the protocol, the presence of other serious conditions (including mental illnesses) requiring concurrent treatment, significant laboratory abnormalities, a history of substance abuse or drug use, combined with psychological, social, familial, or geographic factors, which could impact the subject's safety or the collection of data and samples.","85 Years",{"count":172,"type":20},32,"1.1. Main Objectives The objective response rate (ORR) determined by the researchers based on RECIST v1.1 was used to evaluate the efficacy of systemic therapy (carrycept combined with apatinib) in combination with or without local treatment (surgery, radiotherapy, or ablation therapy) for patients with advanced hepatocellular carcinoma with pulmonary metastases.\n\n1.2. Secondary objectives Through efficacy indicators such as progression-free survival (PFS) and objective response rate (ORR) determined by researchers based on RECIST v1.1 and mRECIST, evaluate the efficacy of systemic therapy (carrietumab combined with apatinib) combined or not with local treatment (surgery, radiotherapy, or ablation therapy) for patients with advanced hepatocellular carcinoma with pulmonary metastases.\n\nEvaluate the safety of combining systemic therapy (caretuximab-rbsm in combination with apatinib) with or without local treatment (surgery, radiotherapy, or ablation therapy) for patients with advanced hepatocellular carcinoma with pulmonary metastases.\n\n1.3. Exploratory Purpose Evaluate the cumulative duration (the sum of the time spent in a NED state) and the safety of local treatments for patients who have undergone comprehensive treatment and have no detectable active lesions on imaging studies (NED).\n\nExplore the correlation between biomarkers and the efficacy of combined treatment regimens.\n\nExplore the relationship between the number, diameter, and treatment outcomes of pulmonary metastases in hepatocellular carcinoma.",[175],"Hepatecellular Carcinoma","2026-03-15",{"date":178,"type":30},"2026-03-19",{"date":180,"type":20},"2026-03-02",{"date":182,"type":20},"2028-12-31",{"name":36,"class":37},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":51,"phases":193,"briefSummary":195,"conditions":196,"keywords":199,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":4},"100624637","phase-4-effect-of-tegileridine-on-postoperative-bowel-function-recovery-in-abdominal-surgery-100624637","NCT07412223","Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery","Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery: A Multicenter, Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Scheduled to undergo elective abdominal surgery under general anesthesia.\n2. Age ≥ 18 years.\n3. Body Mass Index (BMI) between 18 and 30 kg\u002Fm².\n4. American Society of Anesthesiologists (ASA) physical status classification of I to III.\n5. Requires postoperative analgesia and is capable of correctly using a patient-controlled intravenous analgesia (PCIA) pump.\n6. Understands the trial objectives and voluntarily participates, providing written informed consent.\n\nExclusion Criteria:\n\n1. Undergoing gastrointestinal tract surgery.\n2. Has advanced cancer with ascites or extensive metastasis, or is receiving systemic chemotherapy\u002Fradiotherapy, or requires postoperative hyperthermic intraperitoneal chemotherapy (HIPEC).\n3. Diagnosed or suspected gastrointestinal obstruction or emptying disorder.\n4. History of severe cardiovascular or cerebrovascular disease (e.g., severe sinus bradycardia, myocardial infarction, unstable angina, grade II or higher atrioventricular block, history of arrhythmia, NYHA class II or higher heart failure, ischemic stroke) or abnormal QTcF interval at screening ( \\>450 ms for males, \\>470 ms for females).\n5. Comorbid psychiatric or neurological disorders (e.g., schizophrenia, depression, epilepsy) or cognitive dysfunction.\n6. Known allergy to opioid drugs or any component of the trial medications.\n7. Current acute or chronic pain conditions, or presence of hyperalgesia or other sensory disorders.\n8. Long-term opioid therapy (defined as receiving \\>15 mg morphine milligram equivalents per day for more than 3 days per week, over a period exceeding 1 month within the 12 months prior to surgery).\n9. Pregnant or breastfeeding women, or those with a positive pregnancy test at screening or on the day of surgery; or participants (including males) planning for pregnancy.\n10. Significant hepatic or renal dysfunction (e.g., ALT\u002FAST \\> 3 times the upper limit of normal, or requiring renal replacement therapy).\n11. Planned admission to the Intensive Care Unit (ICU) for postoperative management.\n12. Participation in another interventional clinical trial within the 3 months prior to randomization.\n13. Any other condition deemed by the investigator as unsuitable for participation in this trial.",{"count":192,"type":20},152,[194],"PHASE4","Title: Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery: A Multicenter, Randomized, Controlled Trial\n\nThe goal of this clinical trial is to evaluate the effectiveness and safety of tegileridine, a biased μ-opioid receptor agonist, for patient-controlled intravenous analgesia (PCIA) after abdominal surgery.\n\nThe main question it aims to answer is:\n\nIs tegileridine superior to morphine in promoting the recovery of gastrointestinal function within 72 hours after abdominal surgery?\n\nResearchers will compare the experimental group (receiving Fumarate Tegileridine Injection) to the active control group (receiving Morphine Hydrochloride Injection). Both groups will also receive dexmedetomidine in their PCIA pumps. This comparison will determine if tegileridine is more effective for bowel recovery and has a better safety profile.\n\nParticipants who are scheduled for elective abdominal surgery under general anesthesia will:\n\n1. Be randomly assigned to receive either a tegileridine-based or a morphine-based pain relief pump after surgery.\n2. Use the patient-controlled analgesia (PCA) pump for up to 72 hours postoperatively to manage their pain.\n3. Be assessed for the time it takes for their bowel function to return (tolerating food and having gas or bowel movement).\n4. Have their pain levels, overall recovery quality, sleep quality, and any side effects monitored during hospitalization.\n5. Be followed up 30 days after surgery.",[197,198],"Pain, Postoperative","Postoperative Ileus",[200,198,201,202,203],"Tegileridine","Postoperative Pain","GI-3 composite endpoint","Abdominal Surgery","2026-02-13",{"date":206,"type":30},"2026-02-17",{"date":208,"type":20},"2026-02-24",{"date":210,"type":20},"2027-02-24",{"name":36,"class":37},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":220,"targetDuration":4,"studyType":51,"phases":222,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100621390","phase-3-effects-of-butylphthalide-enhanced-with-tenecteplase-on-neurological-function-in-mild-disabling-acute-ischemic-stroke-100621390","NCT07369999","Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke","Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke -A Prospective, Multicenter, Randomized, Double-blind, Active-controlled Trial","BENEFIT-2","Inclusion Criteria:\n\n* 1\\. Age 18-80 years, regardless of gender.\n* 2\\. Clinically diagnosed with acute ischemic stroke and meets the criteria for tenecteplase intravenous thrombolysis.\n* 3\\. Onset of the current stroke within 4.5 hours.\n* 4\\. Clinical diagnosis of minor ischemic stroke with a NIHSS score of 2-5, accompanied by persistent unilateral limb weakness or speech symptoms, defined as a score ≥1 on either the language item or any one limb item of the NIHSS\n* 5\\. Pre-stroke mRS score ≤1.\n* 6\\. The subject or their legal representative is able and willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. History of intracranial hemorrhage.\n* 2\\. Patients who have received or plan to undergo mechanical thrombectomy.\n* 3\\. History of major head trauma or stroke within the past 3 months.\n* 4\\. Known severe liver\u002Fkidney dysfunction or patients receiving dialysis (severe liver dysfunction: ALT\u002FAST \\>3 times the upper limit of normal; severe kidney dysfunction: serum creatinine \\>3.0 mg\u002Fdl \\[265.2 μmol\u002FL\\] or GFR \\\u003C30 ml\u002Fmin\u002F1.73 m²).\n* 5\\. Systolic blood pressure \\\u003C90 mmHg or \\>220 mmHg.\n* 6\\. Patients with bradycardia (heart rate \\\u003C60 beats\u002Fmin) or sick sinus syndrome.\n* 7\\. History of drug\u002Ffood allergy or known allergy to the components of the study drugs.\n* 8\\. Patients treated with drugs containing butylphthalide after stroke onset.\n* 9\\. History of congenital\u002Facquired hemorrhagic diseases, coagulation factor deficiency, or thrombocytopenic diseases.\n* 10\\. Pregnant or lactating subjects or subjects planning to become pregnant within 90 days.\n* 11\\. Subjects with severe mental disorders or dementia who cannot cooperate with informed consent and follow-up.\n* 12\\. Subjects with concurrent malignant tumors or severe systemic diseases, with an expected survival of \\\u003C90 days.\n* 13\\. Patients who have participated in other clinical interventional studies within 30 days prior to randomization, or who are currently participating in other clinical interventional studies;\n* 14\\. Patients who are unable to complete follow-up visits as scheduled;\n* 15\\. Any other reasons that, in the investigator's opinion, render the patient unsuitable for participation in the study.",{"count":221,"type":20},1062,[223],"PHASE3","Abstract Background Intravenous thrombolysis is the cornerstone of early treatment for acute ischemic stroke (AIS), but some still have a poor prognosis, especially in patients with mild disabling stroke. Tenecteplase (TNK), a novel thrombolytic agent with favorable pharmacokinetic profiles, and butylphthalide (NBP), a multi-targeted neuroprotective drug, have shown promising efficacy in separate clinical applications. However, evidence for their combined use in mild disabling AIS is lacking.\n\nAim To determine whether TNK combined with NBP can improve functional outcomes compared with TNK monotherapy in patients with mild disabling AIS who receive thrombolysis within 4.5 hours of onset.\n\nDesign BENEFIT-2 is a prospective, multicenter, randomized, double-blind, active-controlled trial. Eligible patients are randomized 1:1 to receive either TNK plus NBP (combination group) or TNK plus placebo (control group) via stratified block randomization. The combination group receives sequential NBP sodium chloride injection (25mg\u002F100ml, twice daily for 7 days) and oral NBP soft capsules (0.2g, three times daily) until day 14; the control group receives matching placebos.\n\nEligibility criteria include age 18-80 years, onset time ≤4.5 hours, NIHSS score 2-5 with disabling manifestations (hemianopia, aphasia, or limb weakness), and pre-stroke modified Rankin Scale (mRS) score ≤1.\n\nStudy outcomes The primary outcome is the proportion of patients with mRS score 0-1 at 90±7 days. Secondary outcomes include changes in NIHSS score, recurrence of ischemic stroke, composite vascular events, quality of life (assessed by EQ-5D scale), and ischemic penumbra salvage rate. Safety outcomes include symptomatic intracranial hemorrhage (sICH), vascular death, all-cause death, and adverse events within 90 days.\n\nDiscussion BENEFIT-2 is the first large-scale randomized trial to evaluate the synergistic effect of \"vascular recanalization + neuroprotection\" in mild disabling AIS. By combining TNK and NBP, this study aims to fill the evidence gap and provide a new therapeutic option to improve functional recovery in this specific population.",[226],"Mild Disabling Acute Ischemic Stroke",[226,228,229],"Butylphthalide","Tenecteplase","2026-02-11",{"date":232,"type":30},"2026-02-12",{"date":234,"type":20},"2026-02-01",{"date":236,"type":20},"2029-06-30",{"name":36,"class":37},{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":51,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":38},"100615737","acupuncture-for-refractory-rosacea-a-study-on-its-effectiveness-and-safety-100615737","NCT07296497","Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety","A Randomized, Multicenter, Single-blind, Sham-controlled Clinical Trial on the Efficacy and Safety of Acupuncture in the Treatment of Refractory Rosacea.","Inclusion Criteria:\n\n1. Patients diagnosed with refractory rosacea, defined as those who have received at least 12 weeks of conventional oral medication (such as doxycycline), with or without other treatments (e.g., topical medications or intense pulsed light \\[IPL\\] therapy), but remain treatment-resistant - characterized by no improvement of erythema by at least one CEA grade, persistent erythema ≥ grade 3, or recurrent flushing that affects quality of life (DLQI indicating at least a moderate impact); or patients who experience frequent relapses during the 12-week treatment period;\n2. Age between 18 and 65 years, inclusive, with no restriction on sex;\n3. Individuals who fully understand the purpose and significance of the study, voluntarily agree to participate, sign the informed consent form (ICF), and are willing to comply with all study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n1. Women who are pregnant, breastfeeding, or planning to become pregnant in the near future;\n2. Patients with diabetes mellitus or moderate to severe systemic diseases affecting the liver, kidney, lung, or hematologic system;\n3. Patients with depression or other psychiatric disorders;\n4. Individuals with severe abnormal reactions to acupuncture (e.g., syncope during acupuncture, allergy to acupuncture needles);\n5. Patients with rosacea accompanied by nasal hypertrophy or other facial dermatoses (such as seborrheic dermatitis, eczema) or facial manifestations of other systemic diseases (such as dermatomyositis, systemic lupus erythematosus);\n6. Individuals with a bleeding tendency or coagulation disorders, or with skin damage, infection, or other lesions at the acupuncture sites;\n7. Patients who discontinued oral antibiotics less than 1 month prior to enrollment; discontinued non-antibiotic oral medications less than 15 days prior (or isotretinoin less than 3 months prior); or discontinued topical medications less than 1 week prior;\n8. Patients who are expected to be unable to comply with follow-up requirements;\n9. Individuals who have participated in any other clinical trial within 1 month before screening (defined as having signed an informed consent form and received an investigational drug\u002Fdevice\u002Fplacebo);\n10. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.","65 Years",{"count":247,"type":20},104,[53],"This study is a randomized, multicenter, sham-controlled clinical trial designed to evaluate the efficacy and safety of acupuncture for patients with refractory rosacea. A total of 104 participants will be enrolled and randomly assigned in a 1:1 ratio to the acupuncture group or the sham acupuncture group (52 participants in each group, regardless of sex). The primary aim is to determine whether acupuncture can effectively alleviate facial erythema and flushing episodes compared with sham stimulation.",[251],"Rosacea",[253,254],"rosacea","acupuncture","2026-01-28",{"date":257,"type":30},"2026-01-30",{"date":259,"type":30},"2025-12-24",{"date":261,"type":20},"2027-04-30",{"name":36,"class":37},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":51,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":4},"100621686","phase-4-vunakizumab-combined-with-recaticimab-in-subjects-with-moderate-to-severe-plaque-psoriasis-and-dyslipidemia-100621686","NCT07373847","Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia","A Single-center, Randomized, Placebo-controlled Trial Study to Compare Efficacy, Safety and Tolerability of Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia","Inclusion Criteria:\n\n\\-\n\nSubjects who meet all of the following criteria may be enrolled in this study:\n\nAdults aged 18 to 75 years, inclusive.\n\nClinically confirmed diagnosis of psoriasis.\n\nAt screening or on Day 1 of study treatment, a PASI score ≥10, BSA involvement ≥10%, and PGA score ≥3.\n\nPresence of dyslipidemia at screening or on Day 1 of study treatment, defined as fasting LDL-C ≥2.6 mmol\u002FL and \\\u003C4.9 mmol\u002FL in subjects without concomitant atherosclerotic cardiovascular disease (ASCVD).\n\nFasting triglycerides (TG) \\\u003C5.6 mmol\u002FL and 10-year ASCVD risk score \\\u003C10%.\n\nWomen of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline, and must agree to use effective contraception throughout the study and for 30 days after the end of the study.\n\nSubjects must voluntarily participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Subjects meeting any of the following criteria will be excluded from the study:\n\nPresence of non-plaque psoriasis at screening or on Day 1 of the study, including guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis.\n\nFever or active infection within 7 days prior to study initiation.\n\nHistory of serious infection within 60 days prior to study initiation (including but not limited to bacterial, viral, or fungal infections requiring hospitalization or intravenous antimicrobial therapy), or any untreated infection.\n\nHistory of chronic infection, such as chronic pyelonephritis or chronic osteomyelitis.\n\nPositive hepatitis B virus (HBV) DNA with abnormal liver function, or HBV DNA \\>1 × 10⁵ copies\u002FmL, indicating active infection.\n\nPositive test results for human immunodeficiency virus (HIV) or Treponema pallidum (syphilis) antibodies.\n\nClinical signs or symptoms suggestive of active tuberculosis (TB) during screening (e.g., fever, cough, night sweats, weight loss), or evidence of current or active pulmonary TB on chest imaging (X-ray or CT) during screening or within 6 months prior to screening.\n\nNew York Heart Association (NYHA) class III or IV heart failure, or left ventricular ejection fraction \\\u003C30%.\n\nDiagnosis within 3 months prior to randomization of new-onset myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, or stroke.\n\nType 1 diabetes mellitus, poorly controlled type 2 diabetes mellitus (HbA1c ≥10%), or diabetes with multiple organ comorbidities.\n\nSCORE (Systematic Coronary Risk Evaluation) ≥10%.\n\nDuring screening, uncontrolled hypertension (defined as systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg) or moderate to severe renal impairment, defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m².\n\nOngoing active liver disease or liver function abnormalities, defined as ALT and\u002For AST ≥3× the upper limit of normal (ULN).\n\nPresence of malignancy.\n\nHistory of severe drug allergy, or known hypersensitivity to funakinzumab, ricazinumab, or any of their excipients.\n\nPregnant or breastfeeding women, women planning pregnancy during the study period, or male or female subjects unwilling to use contraception.\n\nReceipt of systemic oral or intravenous treatment prior to screening without completion of the required washout period, as defined below:\n\n1. Use of TNF-α, IL-12\u002F23, IL-17, or IL-23 monoclonal antibodies (e.g., adalimumab, ustekinumab, ixekizumab, secukinumab, guselkumab) within 3 months prior to screening;\n2. Use of systemic psoriasis treatments (including but not limited to methotrexate, JAK inhibitors, acitretin, cyclosporine, oral or injectable corticosteroids) within 4 weeks prior to screening;\n3. Use of topical psoriasis treatments (including but not limited to corticosteroids, vitamin D₃ analogues, calcineurin inhibitors, tapinarof) within 2 weeks prior to screening;\n4. Receipt of phototherapy (including oral or topical PUVA, UVB, tanning beds, or therapeutic sun exposure) within 4 weeks prior to screening;\n5. Use of statins, cholesterol absorption inhibitors, or fibrates within 4 weeks prior to screening.\n\nLaboratory abnormalities at screening meeting any of the following criteria:\n\n1. Absolute white blood cell count \\\u003C3,000\u002Fmm³;\n2. Absolute lymphocyte count \\\u003C500\u002Fmm³;\n3. Absolute neutrophil count \\\u003C1,000\u002Fmm³;\n4. Platelet count \\\u003C100,000\u002Fmm³;\n5. Hemoglobin \\\u003C9 g\u002FdL;\n6. ALT and\u002For AST \\>3× ULN;\n7. Total unconjugated and\u002For conjugated bilirubin \\>2× ULN;\n8. Clinically significant electrocardiogram (ECG) abnormalities;\n9. Any other laboratory abnormality deemed by the investigator to interfere with study completion or interpretation of study results.","75 Years",{"count":272,"type":20},40,[194],"The aim is to evaluate the safety and efficacy of vunakizumab combined with recaticimab versus vunakizumab combined with placebo in the treatment of plaque psoriasis with dyslipidemia.",[276],"Plaque Psoriasis","2026-01-22",{"date":255,"type":30},{"date":280,"type":20},"2026-01-20",{"date":282,"type":20},"2027-08-30",{"name":36,"class":37},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":301,"leadSponsor":303,"locationsCount":4},"100616668","integrating-plasma-metagenomics-and-host-response-for-accurate-diagnosis-of-infected-pancreatic-necrosis-in-a-prospective-multicenter-cohort-of-acute-necrotizing-pancreatitis-100616668","NCT07308600","Integrating Plasma Metagenomics and Host Response for Accurate Diagnosis of Infected Pancreatic Necrosis in a Prospective Multicenter Cohort of Acute Necrotizing Pancreatitis","PROMOTE","Inclusion Criteria:\n\n1. Confirmed acute necrotizing pancreatitis (Revised Atlanta 2012) within 48 h of symptom onset\n2. Age ≥14 years\n3. Written informed consent\n\nExclusion Criteria:\n\n1. Invasive interventions including percutaneous catheter drainage (PCD) and surgical necrosectomy have already been performed prior to admission.\n2. Confirmed infection outside of pancreas, including pulmonary infection, urinary tract infection.\n3. Pregnancy .\n4. Acute recurrent pancreatitis",{"count":292,"type":20},200,"This study is being done to find a faster and more accurate way to tell whether the necrosis in patients with acute necrotizing pancreatitis (ANP) has become infected. In the absence of microbiological confirmation, clinicians often have to initiate empirical antibiotic therapy for suspected pancreatic infection-a practice supported by current guidelines but one that may contribute to antimicrobial resistance. In this study, the investigators will combine metagenomic next-generation sequencing (mNGS) which could improve the accuracy of infected pancreatic necrosis (IPN) diagnosis and host transcriptional response analysis which could discriminate infectious and noninfectious inflammatory syndromes. In a prospective, multicentre, cohort study, 200 consecutive patients ≥ 14 years with ANP will be enrolled at four tertiary hospitals from Novemeber 2025 to December 2026. If validated, this single-blood approach could enable early, pathogen-directed therapy, curtail unnecessary antibiotics and expedite surgical timing in ANP.",[295,296],"Acute Necrotizing Pancreatitis","Infected Pancreatic Necrosis","2026-01-06",{"date":299,"type":30},"2026-01-08",{"date":257,"type":20},{"date":302,"type":20},"2026-12-30",{"name":36,"class":37},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":312,"targetDuration":97,"studyType":22,"phases":4,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":322,"leadSponsor":324,"locationsCount":4},"100616769","china-atrial-fibrillation-with-complex-metabolic-disorder-cohort-study-came-cohort-100616769","NCT07309913","China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort)","China Atrial Fibrillation With Complex Metabolic Disorders Cohort Study (CAME Cohort)","CAME Cohort","Inclusion Criteria\n\n* Meet the diagnostic criteria for atrial fibrillation: Single-lead electrocardiogram (≥30 seconds) or 12-lead electrocardiogram (≥10 seconds) shows disappearance of P waves, replaced by fibrillation waves (f waves) with irregular amplitude, morphology and duration, and absolutely irregular RR intervals.\n* Aged ≥ 18 years.\n* Willing to sign the informed consent form and cooperate with long-term follow-up.\n\nExclusion Criteria\n\n* Suffering from infective endocarditis or myocarditis.\n* Having clear etiological factors of atrial fibrillation caused by hyperthyroidism, and the etiology has not been effectively controlled.\n* Suffering from severe mental illness and being unable to comply with the study requirements.\n* Pregnant women.\n* Patients with malignant tumors or substance abuse (e.g., cocaine, heroin).",{"count":313,"type":20},3459,"The number of atrial fibrillation (AF) patients in China is approximately 32.76 million, with a prevalence rate of 2.3%. AF is associated with severe outcomes such as stroke and heart failure. Metabolic disorders (e.g., obesity, diabetes mellitus, dyslipidemia) are closely linked to the onset and prognosis of AF. However, the epidemiological characteristics and disease burden of AF combined with metabolic disorders in China remain unclear. Additionally, the impact of complex multi-dimensional metabolic disorders on AF prognosis requires further investigation, and current clinical guidelines lack targeted management recommendations for this population.",[316,317],"Atrial Fibrillation (AF)","Metabolic Disorders","2025-12-15",{"date":320,"type":30},"2025-12-30",{"date":234,"type":20},{"date":323,"type":20},"2036-06-01",{"name":36,"class":37},{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":16,"minAge":332,"maxAge":270,"enrollmentInfo":333,"targetDuration":4,"studyType":51,"phases":335,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100614209","treatment-of-moderate-to-severe-atopic-dermatitis-with-ivarmacitinib-in-adolescents-and-adults-100614209","NCT07276620","Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults","A Study on the Efficacy and Safety of Ivarmacitinib in the Treatment of Moderate to Severe Atopic Dermatitis in Adolescents and Adults","Inclusion Criteria:\n\n* Aged between 12 and 75 years;\n* Diagnosed with moderate-to-severe atopic dermatitis (AD) ;\n* Participants (and legal representatives for adolescents) able to understand and communicate with the investigator.\n\nExclusion Criteria:\n\n* Subject has any of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary:\n\n  1. Absolute lymphocyte count of \\\u003C0.50 x 10\\^9 \u002FL (\\\u003C500\u002Fmm3);\n  2. Absolute Neutrophil Count (ANC) of \\\u003C1 X 10\\^9\u002FL (\\\u003C1000\u002Fmm3);\n  3. Hemoglobin level \\\u003C 80 g\u002FL.\n* Subject has any malignancies or has a history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.\n* Subject with a prior history of thromboembolic events, including deep vein thromboses (DVT), pulmonary embolism, cerebrovascular accidents and those with known inherited conditions that predispose to hypercoagulability.\n* Presence of an active severe acute or chronic bacterial, fungal, or viral infection requiring systemic therapy.\n* Subjects with active tuberculosis or known active hepatitis B and\u002For hepatitis C infection.\n* Subjects with clinically significant diseases of the heart, liver, kidney, or other major organ systems.\n* Female subject who is pregnant, breastfeeding, or considering pregnancy during the study.","12 Years",{"count":334,"type":20},1000,[53],"Atopic dermatitis (AD) is a skin condition characterized by a rash and itching, resulting from skin inflammation. Ivarmacitinib is an approved medication for treating AD.\n\nThis study aims to evaluate the effectiveness and safety of Ivarmacitinib in the treatment of moderate-to-severe atopic dermatitis under real-world conditions. It will assess the time to pruritus improvement and skin lesion clearance, collect large-sample safety data, analyze disease improvement across patient subgroups with different baseline characteristics, and explore the impact of various maintenance treatment regimens on disease recurrence.\n\nIt is expected that there will be no additional burden for participants in this trial.",[338],"Atopic Dermatitis (AD)",[340,341],"Atopic Dermatitis","Ivarmacitinib","2025-12-10",{"date":344,"type":30},"2025-12-11",{"date":346,"type":20},"2025-11-30",{"date":348,"type":20},"2029-01-30",{"name":36,"class":37},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":16,"minAge":358,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":51,"phases":361,"briefSummary":362,"conditions":363,"keywords":367,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":377,"locationsCount":38},"100611085","phase-4-paracetamol-and-mannitol-injection-and-postoperative-delirium-100611085","NCT07235995","Paracetamol and Mannitol Injection and Postoperative Delirium","Impact of Paracetamol and Mannitol Injection Analgesia on Postoperative Delirium in Elderly Patients After Non-cardical Surgery: A Randomized Controlled Trial","PAPOD-ES","Inclusion Criteria:\n\n* Age ≥ 60 years;\n* Admitted to ICU after a noncardiac surgical procedure\n* Moderate to severe acute pain, with a postoperative pain score ≥ 5 based on the 11-point Numerical Pain Rating Scale (NPRS)\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Preoperative medical history: schizophrenia, epilepsy, Parkinson's disease, or severe myasthenia gravis\n* History of psychiatric disease or significant neurocognitive disorder such as dementia or retardation, making POD assessment impossible\n* Language or communication barrier making POD assessment impossible\n* Intracranial surgery\n* Severe hepatic dysfunction prohibiting the use of acetaminophen per the standard of care\n* Participation in a competing study within 30d\n* Patients experienced intraoperative or postoperative complications, and the investigator determined the subject was unsuitable to continue participation in the study\n* Intolerant to paracetamol or opioid drugs","60 Years",{"count":360,"type":20},1092,[194],"The aim of this multi-center RCT is to investigate the effect of intravenous acetaminophen (paracetamol and mannitol injection) on postoperative delirium, comparing with intravenous sufentanil, in elderly noncardiac surgical patients admitted to ICU.",[364,365,366],"Postoperative Delirium","Elderly","Non Cardiac Surgery",[368,369,365,370],"Postoperative delirium","Intravenous acetaminophen","Noncardiac surgical patients","2025-11-17",{"date":373,"type":30},"2025-11-19",{"date":375,"type":20},"2025-12-01",{"date":261,"type":20},{"name":36,"class":37},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":386,"targetDuration":4,"studyType":51,"phases":388,"briefSummary":389,"conditions":390,"keywords":393,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":38},"100592393","neuroprotection-bundles-for-comatose-survivors-following-cardiac-arrest-100592393","NCT06992843","Neuroprotection Bundles For Comatose Survivors Following Cardiac Arrest","A Multicenter, Prospective, Stepped Wedge Cluster Randomized Controlled Study on the Effect of Neuroprotection Bundles on the Improvement of Neurological Outcomes After Cardiopulmonary Resuscitation","LAPTOPS","Inclusion Criteria:\n\n* Age ≥ 18 years and \\\u003C 80 years\n* Patients of in-hospital or out-of-hospital cardiac arrest who have returned -spontaneous circulation (ROSC) after cardiopulmonary resuscitation and do not require CPR for more than 20 minutes;\n* Patients who are unconscious after ROSC, defined as FOUR motor response score \\\u003C 4 points or GSC ≤ 8 points;\n* Family members or legal representatives signed informed consent.\n\nExclusion Criteria:\n\n* Unwitnessed cardiac arrest, estimated time from cardiac arrest to start of CPR \\> 30 minutes;\n* Time from cardiac arrest to ROSC \\> 60 minutes;\n* Patients who woke up immediately after ROSC by CPR;\n* End-stage diseases;\n* Cardiac arrest considered to be caused by neurological diseases;\n* The patient was in a vegetative state before cardiac arrest;\n* The interval from the onset of cardiac arrest to enrollment is \\>72 hours .",{"count":387,"type":20},1008,[53],"The investigators designed LAPTOPS to determine the effectiveness of a goal-directed neuroprotection bundles of active management including body temperature,PaCO2,PaO2,position,Blood glucose ,blood sodium,Blood pressure and Lactate vs. usual care in adult post-cardiac arrest care.\n\nLAPTOPS is a large-scale pragmatic clinical trial to provide reliable evidence over the effectiveness of a widely applicable goal-directed care bundle in acute phase of adult post-cardiac arrest care.",[391,392],"Cardiac Arrest","Post-cardiac Arrest Care",[394,395,396,397,398,399],"post-cardiac arrest care","neuroprotection","cardiac arrest","Care Bundle","Clinical Trial","Stepped-wedge Cluster","2025-11-14",{"date":402,"type":30},"2025-11-18",{"date":404,"type":30},"2025-10-22",{"date":406,"type":20},"2027-08",{"name":36,"class":37},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":416,"conditions":417,"keywords":419,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":4},"100604574","diagnosis-of-intracranial-hypertension-using-tccd-onsd-and-odh-by-bedside-ultrasound-100604574","NCT07151287","Diagnosis of Intracranial Hypertension Using TCCD, ONSD and ODH by Bedside Ultrasound","Inclusion Criteria:\n\n* Traumatic brain injury;\n* Received invasive ICP monitoring;\n* age ≥ 18 years old.\n\nExclusion Criteria:\n\n* Severe eyeball \u002F eyelid damage prevents transorbital ultrasound examination;\n* Allergy to ultrasound coupling agent;\n* Pregnant or lactating females.",{"count":415,"type":20},64,"The goal of this observational study is to investigate several means of measuring intracranial pressure (ICP) non-invasively in patients who had head trauma and received implantation of invasive ICP monitor device. The main questions it aims to answer are:\n\nWhat are the diagnostic efficacies of Transcranial Color-Coded Doppler Ultrasound (TCCD), Optic Nerve Sheath Diameter (ONSD) and Optic Disc Height (ODH) (the 3 non-invasive way of measuring ICP) compared with invasive ICP monitor? Participants will receive simultaneous non-invasive measurements of TCCD, ONSD and ODH along with during the days of invasive ICP monitoring. The data will be compared among the techniques to study the diagnostic efficacy.",[418],"Traumatic Brain Injury",[420,421,422,423,424],"traumatic brain injury","craniocerebral trauma","brain trauma","intracranial pressure","transcranial Doppler ultrasound","2025-09-01",{"date":427,"type":30},"2025-09-03",{"date":429,"type":20},"2025-09-15",{"date":431,"type":20},"2027-07-01",{"name":36,"class":37},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":270,"enrollmentInfo":440,"targetDuration":4,"studyType":51,"phases":442,"briefSummary":443,"conditions":444,"keywords":447,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":38},"100556857","phase-4-the-efficacy-and-safety-of-oliceridine-fumarate-injection-for-acute-pain-after-abdominal-surgery-100556857","NCT06530563","the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery","the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery: a Randomized, Double-blind, Positive-drug Parallel-controlled, Multi-center Clinical Study","Inclusion Criteria:\n\n1.Preoperative inclusion criteria\n\n1. aged ≥18 years and ≤75 years at screening;\n2. Plan to undergo open or laparoscopic abdominal surgery, and the estimated operative time more than 2 hours.\n3. able to understand and comply with research procedures and requirements, and can provide a written informed consent.\n\n2.postoperative inclusion criteria:\n\n1. patients who required open or laparoscopic surgery;\n2. According to the investigator's judgment, the patient had recovered sufficiently from the intraoperative anesthesia protocol to accurately complete the protocol-specified questionnaire;\n\nExclusion Criteria:\n\n1.preoperative exclusion criteria:\n\n1. ASA grade \\>III\n2. existing other acute or chronic pain conditions;\n3. body mass index (BMI) \\\u003C 18 or \\> 30 kg\u002Fm2;\n4. with sleep apnea syndrome; 5 ) long-term opioid treatment, defined as receiving more than 15mg morphine equivalent units per day on more than 3 days per week for a period of more than 1 month in the 12 months prior to surgery;\n\n6\\) suffering from mental or nervous system diseases (such as epilepsy, depression, schizophrenia, etc.), chronic obstructive pulmonary disease or pulmonary heart disease, heart failure, severe arrhythmia, etc; 7) with severe liver and kidney dysfunction; 8) Other conditions considered by the investigator to be inappropriate for enrollment.\n\nPostoperative exclusion criteria:\n\n1. intraoperative, postoperative or anesthetic deviations that may affect the efficacy and safety evaluation in the study;\n2. evidence of hemodynamic instability or respiratory insufficiency.",{"count":441,"type":20},606,[194],"The goal of this clinical trial is to learn if Oliceridine fumarate injection works to treat acute pain after abdominal surgery. It will also learn about the safety of Oliceridine fumarate injection. The main questions it aims to answer are:\n\n1. Does Oliceridine fumarate injection works to treat acute pain after abdominal surgery?\n2. Does Oliceridine fumarate injection lead to less adverse effect?\n\nResearchers will compare Oliceridine fumarate injection to a positive-drug (Sufentanil Citrate) to see if Oliceridine fumarate injection not inferior to sufentanil in the efficacy and safety for acute pain after abdominal surgery.\n\nParticipants will:\n\n1. Receive patient controlled analgesia treat using Oliceridine or sufentanil after surgery\n2. Be followed up every 6 hours until 48 hours after surgery or before discharge",[445,446],"Acute Pain","Opioid Analgesic Adverse Reaction",[448,449,450],"Oliceridine","acute pain after surgery","abdominal surgery","2025-08-18",{"date":453,"type":30},"2025-08-19",{"date":455,"type":20},"2025-08",{"date":457,"type":20},"2026-05",{"name":36,"class":37},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":465,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":468,"conditions":469,"keywords":476,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":490,"locationsCount":38},"100602692","a-vision-language-foundation-model-for-brain-disease-diagnosis-from-multimodal-data-100602692","NCT07126821","A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data","Inclusion Criteria:\n\nPatients with brain diseases:\n\n* Patients with brain tumors were pathologically diagnosed.\n* Patients with other brain diseases were correctly diagnosed.\n* The clinical case data of all patients were complete.\n\nNon-brain disease population:\n\n* All patients have complete clinical case data, complete brain MRI, no history brain diseases, no brain surgery or other brain diseases that affect the diagnosis and observation of MR imaging.\n\nExclusion Criteria:\n\n* Cases in which MRI were incomplete or with significant noise and artifacts.",true,{"count":467,"type":20},100000,"The goal of this observational study is to develop an innovative, comprehensive, and explainable AI vision-language foundation model (VLM) to advance the diagnosis and interpretation of brain diseases using multi-modal data. We will include patient demographics, medical imaging data (such as MRI, CT, and PET scans), histopathological data, genomic data when available, and other necessary laboratory examinations and tests to establish a screening and diagnostic model for brain diseases.",[470,471,472,473,474,475],"Brain (Nervous System) Cancers","Brain Arterial Disease","Neuro-Degenerative Disease","Brain Tumors","Brain Diseases","Neurological di",[477,478,479,480,481,482,483],"brain tumors","brain cancers","brain diseases","foundation model","diagnosis","prediction","neurological diseases","2025-08-15",{"date":486,"type":30},"2025-08-17",{"date":488,"type":30},"2025-05-15",{"date":143,"type":20},{"name":36,"class":37},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":500,"conditions":501,"keywords":508,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":515,"leadSponsor":517,"locationsCount":4},"100601819","development-and-validation-of-a-prognostic-model-for-neurocritical-patients-using-multimodal-brain-monitoring-100601819","NCT07115459","Development and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring","Protocol for Developing and Validating a Multimodal Brain Monitoring-Based Prognostic Model for Neurocritical Patients: A Prospective, Observational, Multicenter Cohort Study","Inclusion Criteria:\n\n1. Aged 18-80 years, no gender restrictions.\n2. Diagnosed with acute brain injury (ABI), including one of the following: large cerebral infarction, supratentorial large-volume intracerebral hemorrhage, subarachnoid hemorrhage, or severe traumatic brain injury, with imaging evidence (CT or MRI) supporting the diagnosis.\n3. On ICU admission, Glasgow Coma Scale (GCS) eye response = 1 (no eye opening) and motor score ≤ 5 (does not follow commands); or within 48 hours, neurological deterioration with no eye opening and motor score reduced to ≤ 5 (total GCS score ≤ 8).\n4. Able to undergo continuous multimodal monitoring, with an expected ICU stay of ≥72 hours.\n5. Informed consent signed by the family or legal representative.\n\nExclusion Criteria:\n\n1. Confirmed brain death on admission or imaging showing irreversible brain herniation.\n2. Severe trauma unrelated to brain injury (e.g., multiple fractures, spinal cord injuries, or visceral rupture) that may interfere with brain function monitoring or outcome assessment.\n3. Pre-existing severe neurological disorders such as epilepsy, severe encephalopathy, or chronic intracranial conditions (e.g., brain tumors or hydrocephalus).\n4. Inability to perform multimodal monitoring due to technical issues (e.g., equipment failure or sensor installation problems).\n5. Predicted survival time \\\u003C24 hours after admission, or family members choose to withdraw treatment.\n6. Refusal to participate in the study by the patient or their legal representative.",{"count":499,"type":20},167,"This study aims to develop and validate a prognostic model for neurocritical patients using multimodal brain monitoring data. By combining data from various monitoring techniques such as EEG, TCD, and NIRS, this model will help predict 90-day outcomes (awake, comatose, or deceased) and support personalized treatment decisions. The study is observational and involves no experimental interventions.",[502,503,504,505,506,507],"Acute Brain Injury Coma","Neurocritical Care","Cerebral Infarction","Intracranial Hemorrhages","Subarachnoid Hemorrhage","Severe Traumatic Brain Injury",[509,510],"Multimodal Brain Monitoring","Prognostic Model","2025-08-03",{"date":513,"type":30},"2025-08-11",{"date":484,"type":20},{"date":516,"type":20},"2026-11-15",{"name":36,"class":37},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":465,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":527,"conditions":528,"keywords":531,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":38},"100590850","xiangya-cardiopulmonary-health-and-disease-cohort-100590850","NCT06972784","Xiangya Cardiopulmonary Health and Disease Cohort","XY-CPHDC","I1 Inclusion and exclusion criteria for retrospective cohorts 1) Inclusion criteria:\n\n1. Patients were either treated or hospitalized in the physical examination center, outpatient and emergency clinic in the Xiangya Hospital of Central South University from January 2010 to April 2025.\n2. Completion of cardiac function (e.g., echocardiography) and pulmonary function (e.g., pulmonary function test) assessment, with an interval of no more than 1 year between the two.\n3. Those who had complete clinical diagnostic and therapeutic information (e.g., medical history, medication records, laboratory test results, imaging reports) except for the cardiopulmonary function test report.\n\n2)Exclusion criteria\n\n1. Patients with complete loss of cardiopulmonary function test reports or key data (e.g., VO2peak, FEV1\u002FFVC, LVEF).\n2. Patients with loss of key clinical diagnostic and treatment data (e.g., medical history, medication records, laboratory test results).\n\n2.1.2 Inclusion and exclusion criteria for prospective cohort\n\n1）Inclusion criteria\n\n1. Patients who have been included in the retrospective cohort.\n2. Voluntarily signed informed consent form to participate in long-term follow-up for ≥3 years.\n3. Able to complete the baseline assessment of the prospective cohort (including cardiopulmonary function retesting, questionnaires, etc.).\n4. Stable conditions for follow-up (e.g., living in the local area, available valid contact information, no plans to move in the short term or go out for a long period of time).\n\n2\\) Exclusion Criteria.\n\n1. Patients who have been excluded from the retrospective cohort or for whom key data are missing.\n2. With severe cognitive impairment, psychiatric disease or verbal communication disorder, unable to cooperate with follow-up and data collection.\n3. Expected survival time \\\u003C3 years (e.g., advanced malignancy, end-stage cardiopulmonary failure, etc.).\n4. Incomplete cardiopulmonary function or other clinical data during the baseline assessment.\n5. Those who plan to participate in other interventional clinical trials that may interfere with the assessment of cardiopulmonary function.",{"count":526,"type":20},30000,"Xiangya Cardiopulmonary Health and Disease Cohort (XY-CPHDC) is a non-intervention study grounded in real-world data. It is designed as a bidrectional clinical cohort combined retrospective and prospective design, in order to evaluate cardiopulmonary function systematically and holistically, integrate physiology and medical theory, and explore the changing pattern of the cardiopulmonary under different health states. Cardiovascular System and Respiratory System are closely linked and interdependent physiological systems, and they play a vital role in maintaining normal life activities in the human body. Patients with cardiopulmonary disease often have conspicuous comorbidity characteristics, however, current measurements of cardiopulmonary function indicators are mostly limited to the assessments of single organ. This pattern of subspecialty care leads to deficiencies in the recognition of cardiopulmonary synergy dysfunction, and there is an urgent need for a more comprehensive and systematic approach to assessment. This study plans to construct a cardiopulmonary holistic assessment cohort, aiming at comprehensively and systematically reveal the intrinsic connection between the cardiopulmonary function in different scenarios, such as resting, exercise, and sleep, to deeply explore the core indicators of cardiopulmonary holistic function, to construct a joint stratification system of cardiopulmonary function, and to map cardiopulmonary comorbidity spectrum, so that they can accurately guide the diagnosis of the disease, the prognostic prediction and the intervention strategies.",[529,530],"Respiratory Function Tests，Heart Function Tests","Cardiopulmonary Function",[532],"Respiratory function tests，Heart Function Tests，Cardiopulmonary function","2025-06-30",{"date":535,"type":30},"2025-07-02",{"date":537,"type":30},"2025-06-01",{"date":539,"type":20},"2035-12-01",{"name":36,"class":37},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":16,"minAge":548,"maxAge":48,"enrollmentInfo":549,"targetDuration":4,"studyType":51,"phases":551,"briefSummary":552,"conditions":553,"keywords":555,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":38},"100520289","l-arginine-for-knee-osteoarthritis-patients-100520289","NCT06054633","L-arginine for Knee Osteoarthritis Patients","Efficacy and Safety of Oral L-Arginine for Pain Relief in Knee Osteoarthritis: a Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Age between 40 and 80 years.\n2. Knee OA according to the American College of Rheumatology (ACR) clinical criteria.\n3. Knee pain lasting 3 months or longer and a score of 7 or greater on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (standardized to range from 0-20).\n4. Kellgren-Lawrence (KL) grade 2 or 3.\n5. Willing to and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Any use of NSAIDs or other analgesics in the past two weeks.\n2. History of injections of corticosteroids in the past three months or hyaluronic acid in the past 6 months in the index knee.\n3. History of arthroscopy or open surgery in the index knee in the past 12 months.\n4. History of a knee replacement in the index knee or planning to receive such a procedure within 3 months.\n5. History of a severe injury in the index knee.\n6. Pain in the index knee caused by inflammatory, autoimmune, neoplastic diseases or other diseases.\n7. Abnormal liver or kidney functions, as defined by alanine transaminase or aspartate aminotransferase \\>two times the upper limit of normal, or blood urea nitrogen or serum creatinine \\>two times the upper limit of normal.\n8. Severe respiratory diseases.\n9. History of coronary artery disease and heart failure.\n10. Uncontrolled hypertension or diabetes mellitus.\n11. Diagnosis of malignant tumors.\n12. Pregnant or contemplating pregnancy or breast-feeding.","40 Years",{"count":550,"type":20},340,[53],"This study will examine the pain-relief efficacy and safety of L-arginine in knee OA patients.",[554],"Osteoarthritis, Knee",[556,557,558],"osteoarthritis","L-arginine","Pain","2025-05-27",{"date":561,"type":30},"2025-06-02",{"date":563,"type":30},"2024-03-20",{"date":565,"type":20},"2025-09-30",{"name":36,"class":37},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":16,"minAge":548,"maxAge":48,"enrollmentInfo":574,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":4},"100591964","establishment-of-diagnosis-and-classification-system-for-lung-interstitial-and-airway-diseases-liad-100591964","NCT06987266","Establishment of Diagnosis and Classification System for Lung Interstitial and Airway Diseases (LIAD)","EDCS-LIAD","Inclusion Criteria:\n\n1. age between 40-80 years old;\n2. inpatients with an admission diagnosis of COPD, Idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, patients with the following diagnoses were screened by chest CT (slice thickness ≤1.5 mm) during hospitalization and by in-hospital or prior pulmonary function;\n3. the inpatients could complete pulmonary function and chest CT examination within 1 month after discharge;\n4. among outpatients, patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, COPD with pulmonary interstitial abnormalities, idiopathic pulmonary fibrosis with airway lesions, nonspecific interstitial pneumonia with airway lesions, pulmonary fibrosis with emphysema syndrome were diagnosed through chest CT (layer thickness ≤1.5mm) and lung function;\n5. provide informed consent.\n\nExclusion Criteria:\n\n1. expected survival less than 12 months;\n2. planned lung transplantation or pneumonectomy within 12 months;\n3. pregnant or lactating women.",{"count":575,"type":20},900,"This study focuses on both hospitalized and outpatient populations. Through a multicenter, retrospective study, it aims to comprehensively characterize:The comorbidity of interstitial lung diseases (ILD) and airway diseases;The comorbidity of ILD with other intrapulmonary diseases;The comorbidity of airway diseases with other intrapulmonary diseases;The comorbidity of ILD and airway diseases with extrapulmonary diseases.Based on these findings, the study seeks to propose classification and diagnostic criteria for ILD and airway disease comorbidities.Additionally, a multicenter, prospective, disease-specific cohort study will be conducted to observe the prognosis of patients with ILD and\u002For airway diseases, identify prognostic factors, and grade the severity of comorbid conditions based on these factors.Finally, the study will analyze the current state of interventions and the medical costs associated with ILD and airway disease comorbidities through a cost-effectiveness analysis, aiming to propose new strategies for integrated disease management.",[578,579],"Interstitial Lung Diseases (ILD)","Airway Disease","2025-05-22",{"date":582,"type":30},"2025-05-23",{"date":584,"type":20},"2025-05-20",{"date":586,"type":20},"2028-11-30",{"name":36,"class":37},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":595,"conditions":596,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":38},"100588205","development-and-application-of-accurate-detection-technology-based-on-multimodal-data-of-breast-cancer-comobid-depression-100588205","NCT06938373","Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression","Inclusion Criteria:\n\n* Pathologically confirmed primary breast cancer; Aged 18-80 years; No prior history of malignancy other than breast cancer; Awareness of their breast cancer diagnosis; Karnofsky Performance Status (KPS) score \\>70; Willing to provide blood, fecal, and saliva samples with signed informed consent.\n\nExclusion Criteria:\n\n* Physician-diagnosed mental disorders before or after breast cancer diagnosis; Severe chronic somatic diseases (e.g., central nervous system disorders, severe head trauma, substance abuse\u002Fdependence, intellectual disability, diabetes, gynecological diseases, cardiovascular diseases, thyroid disorders, etc.); Presence of two or more primary malignancies of different tissue origins; Central nervous system (CNS) metastasis of breast cancer; Clinically diagnosed digestive system diseases (e.g., enteritis, gastritis); Use of antidepressant or anxiolytic therapy during the study; Use of medications that alter gut function or metabolism during the study; Pregnant or lactating women; Radiotherapy or chemotherapy within the past 21 days; Use of antibiotics, probiotics, prebiotics, or synbiotics within 3 months prior to the study; Other reasons deemed unsuitable for participation by investigators.",{"count":334,"type":20},"This study is a prospective, observational clinical research aimed at establishing a multimodal database encompassing clinical information and gut microbiome data from a sample of over 1,000 breast cancer patients comorbid with depression. The research involves collecting cohort sample information from breast cancer patients with comorbid depression, as well as fecal, blood, and saliva specimens for metagenomic sequencing, untargeted metabolite detection, and cortisol level analysis, respectively. Based on the collected multimodal data, diagnostic, efficacy prediction, and prognostic survival prediction models for breast cancer with comorbid depression will be developed. Additionally, a precision prediction cloud platform will be designed and deployed to support data upload, model prediction, and result visualization.",[597],"Breast Neoplasms","2025-04-14",{"date":600,"type":30},"2025-04-22",{"date":602,"type":30},"2025-03-11",{"date":604,"type":20},"2027-04-01",{"name":36,"class":37},{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":465,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":614,"conditions":615,"keywords":621,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":38},"100574173","sleep-disordered-breathing-and-multimorbidity-the-xiangya-sdb-cohort-study-100574173","NCT06755840","Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study","Inclusion Criteria:\n\n* 1\\) Participants who were suspected of sleep disordered breathing must complete at least one overnight sleep monitoring at the Sleep Medicine Center at Xiangya Hospital.\n* 2\\) Participants can finish any assessment for each comorbid system by questionnaires, scales, physical examinations and tests, etc. independently or with the assistance.\n* 3\\) Participants agreed to participate in this study with signing an informed consent form.\n\nExclusion Criteria:\n\n* Participants who refused to participate in this study or whose clinical data was lost.",{"count":613,"type":20},15000,"Sleep disordered breathing (SDB) is one of the most common sleep disorders, including obstructive sleep apnea (OSA), central sleep apnea (CSA), sleep-related hypoventilation, hypoxemia, etc., with OSA being the most prevalent. Also, SDB shows high comorbidities with multisystem diseases. Furthermore, compared to patients with pure SDB, those comorbid with SDB and other disorders like cardiometabolic dysfunction and cognitive impairment experience poorer quality of life, higher rate of disease progression and mortality, and a greater economic burden. Currently, there are limited cohorts to study the associations between SDB and multisystem diseases. The aim of this study is to establish an ambispective clinical cohort for SDB in Xiangya hospital from central-south China (Xiangya Sleep Disordered Breathing Cohort, Xiangya SDB cohort) including retrospective part and prospective part, which covers multi-dimensional data of sleep monitoring, demographic, daily behaviors, clinical manifestations and comorbidities status, life quality, treatment information and evaluation, etc. by self-reported questionnaires and objective assessments and tests. Besides, whole peripheral blood is drawn for following biomarkers study and omics analysis. The main goal is to achieve precise management of SDB and related multimorbidity, containing to early identify risk individuals for multisystem impairment, significantly improve their prognosis and ultimately enhance overall health. In detail: first, to reveal how multisystem impairment related to SDB evolves; second, to identify which indicators closely involve system dysfunction due to SDB; third, to build an efficient model and a cost-effective platform to screen high-risk population and tract therapeutic effect.",[616,617,618,619,620],"Sleep Disordered Breathing (SDB)","Sleep Apnea","Cardiometabolic Diseases","Multimorbidity","Neurodegenerative Diseases",[622,623,624,625,626,627,628,629,630,631],"sleep disordered breathing","obstructive sleep apnea","central sleep apnea","cardiovascular diseases","metabolic diseases","respiratory diseases","nervous system diseases","mental disorders","neoplasms","multimorbidity","2025-04-01",{"date":634,"type":30},"2025-04-03",{"date":636,"type":30},"2025-01-15",{"date":638,"type":20},"2035-10-31",{"name":36,"class":37},""]